CL2015002641A1 - Método para el tratamiento de la enfermedad de parkinson. - Google Patents
Método para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- CL2015002641A1 CL2015002641A1 CL2015002641A CL2015002641A CL2015002641A1 CL 2015002641 A1 CL2015002641 A1 CL 2015002641A1 CL 2015002641 A CL2015002641 A CL 2015002641A CL 2015002641 A CL2015002641 A CL 2015002641A CL 2015002641 A1 CL2015002641 A1 CL 2015002641A1
- Authority
- CL
- Chile
- Prior art keywords
- parkinson
- disease
- treatment
- tolcapona
- entacapona
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 1
- 238000009313 farming Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002641A1 true CL2015002641A1 (es) | 2016-03-18 |
Family
ID=50513395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002641A CL2015002641A1 (es) | 2013-03-13 | 2015-09-11 | Método para el tratamiento de la enfermedad de parkinson. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160022573A1 (https=) |
| EP (2) | EP2968218B1 (https=) |
| JP (2) | JP6472391B2 (https=) |
| KR (1) | KR102209353B1 (https=) |
| CN (2) | CN105209029A (https=) |
| AU (1) | AU2014229127B2 (https=) |
| BR (1) | BR112015022390A8 (https=) |
| CA (1) | CA2904838C (https=) |
| CL (1) | CL2015002641A1 (https=) |
| DK (1) | DK2968218T3 (https=) |
| ES (1) | ES2889626T3 (https=) |
| HR (1) | HRP20211442T1 (https=) |
| HU (1) | HUE056006T2 (https=) |
| IL (1) | IL266648B (https=) |
| MX (1) | MX365206B (https=) |
| PL (1) | PL2968218T3 (https=) |
| PT (1) | PT2968218T (https=) |
| RU (2) | RU2677278C2 (https=) |
| SG (2) | SG10201911731YA (https=) |
| WO (1) | WO2014141261A1 (https=) |
| ZA (1) | ZA201507621B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2432454T3 (pl) | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| TR201808178T4 (tr) | 2010-11-15 | 2018-07-23 | Neuroderm Ltd | Aktif ajanların transdermal dağıtımı için bileşimler. |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| DK3116475T3 (da) * | 2014-03-13 | 2020-12-07 | Neuroderm Ltd | Dopa-decarboxylasehæmmersammensætninger |
| JP6622310B2 (ja) | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CA3065990A1 (en) * | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| US11806326B2 (en) | 2018-01-29 | 2023-11-07 | Jonathan Sackner-Bernstein | Methods for dopamine modulation in human neurologic diseases |
| BR112020017422A2 (pt) * | 2018-03-29 | 2020-12-22 | Avion Pharmaceuticals , Llc | Composição de dose fracionada de levodopa e uso |
| BR112021009353A2 (pt) | 2018-11-15 | 2021-11-23 | Abbvie Inc | Formulações farmacêuticas para administração subcutânea |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| WO2022047298A1 (en) * | 2020-08-31 | 2022-03-03 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| PL1896006T3 (pl) * | 2005-06-08 | 2010-03-31 | Orion Corp | Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| PL2432454T3 (pl) * | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
-
2014
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active Active
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en not_active Ceased
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en not_active Abandoned
-
2024
- 2024-07-05 US US18/764,647 patent/US20250177292A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002641A1 (es) | Método para el tratamiento de la enfermedad de parkinson. | |
| CL2019001685A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| CR20150242A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| MX372669B (es) | Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer. | |
| DOP2016000291A (es) | Composiciones y métodos para modular la expresión del factor b del complemento | |
| UY35821A (es) | Compuesto heterocíclico | |
| ECSP20011578A (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| MX2018003497A (es) | Formulaciones de aminoacidos de liberacion modificada administradas por via oral. | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| CR20150589A (es) | Compuestos de biheteroarilo y usos de los mismos | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| BR112019003577A2 (pt) | métodos de tratamento da semente e produtos resultantes | |
| MX2016011837A (es) | Composiciones de inhibidores de la dopa decarboxilasa. | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| MX2018006706A (es) | Regimenes de dosificacion de melflufen para cancer. | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
| AR106313A1 (es) | Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson | |
| BR112016012505A2 (pt) | composto para tratamento de hipoglicemia severa | |
| AR105047A1 (es) | Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (hsdd) con un tratamiento de combinación de bupropion y trazodona |